middle.news
Vectus Validates VB0004 Safety, Cuts Costs, Eyes China Licensing Deals
12:18pm on Wednesday 30th of April, 2025 AEST
•
Healthcare
Read Story
Vectus Validates VB0004 Safety, Cuts Costs, Eyes China Licensing Deals
12:18pm on Wednesday 30th of April, 2025 AEST
Key Points
Phase Ia/Ib clinical trials confirm VB0004 safety profile
Active commercial discussions led by C14 Consulting Group
Focus on licensing and collaborations to fund further trials
Cash on hand at $370,000 with $200,000 loan facility available
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Vectus Biosystems (ASX:VBS)
OPEN ARTICLE